SCOTTSDALE, Ariz. and GAITHERSBERG, Md., May 19, 2016 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. (“Avant”) (OTCQB:AVDX), an innovative molecular diagnostics company, today announced the acceptance of two posters for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
“We look forward to presenting this important work that was completed with leading clinical collaborators, demonstrating the power of our reverse phase protein array (RPPA) pathway analysis technology,” said Glenn D. Hoke, PhD, incoming Chief Scientific Officer at Avant. “As we move forward, we will be looking to build upon this work by expanding our clinical and collaboration network in order to provide drug development companies and clinicians with the necessary information to better inform treatment and trial recruitment decisions to the ultimate benefit of patients.”
POSTER PRESENTATION #1
Sunday June 5, 8:00 AM – 11:30 AM CT
Abstract #558: Reverse-phase protein microarray (RPPA) analysis of PD-L1 and growth factor receptor signal transduction pathways in hormone receptor (HR)-positive primary breast cancer tissue and correlation with relapse.
Principle Investigator: Alan Lipton, MD, Penn State Hershey Medical Center
Presenter: Suhail M. Ali, MD, MBBS, Penn State Hershey Medical Center, VA Medical Center
Session: Breast Cancer-HER2/ER
Poster Display: Hall A; Poster Board 46; 8:00 AM – 11:30 AM CT
POSTER PRESENTATION #2
Monday June 6, 1:00 PM – 4:30 PM CT
Abstract # 11527: Androgen receptor activation in HER2-negative breast cancer liver metastases.
Principle Investigator: Joyce O’Shaughnessy, MD, Baylor University Center, Texas Oncology
Presenter: Corinne Ramos, Ph.D., Theranostics Health, Gaithersburg, MD
Session: Tumor Biology
Poster Display: Hall A; Poster Board 224; 1:00 PM – 4:30 PM CT
ASCO 2015 Annual Meeting Posters on RPPA Assay
HER3 and paxillin signaling in ER+ HER2- metastatic breast cancer patients receiving letrozole vs. letrozole plus dasatinib in a randomized phase II trial.
About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in biomarker tests that are being developed in the areas of oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® Diagnostic Assays, primarily for breast cancer, to assist clinical oncologists to identify likely responders for roughly 30 FDA-approved drug treatment regimens through its CLIA/CAP. Avant is the leading developer of proteomic technologies for measuring the activation status of key signaling pathways across several different cancer types, including breast, ovarian and pancreatic that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. For more information please visit www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.
Avant’s neurology division owns the rights to MSPrecise™, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test™ for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
For further information please visit www.avantdiagnostics.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant's Form 10-K filed with the Securities and Exchange Commission on January 13, 2016, and other periodic reports filed with the Securities and Exchange Commission.
Investor and Media Contact: Ascendant Partners, LLC Fred Sommer 732-410-9810 email@example.com
Source:Avant Diagnostics, Inc.